Who Wins the U.S. Clinical AI Market? Abridge, Doximity, OpenEvidence, and Epic Go Head-to-Head
Four AI companies are fighting to own U.S. clinical workflows. We break down how Abridge, Doximity, OpenEvidence, and Epic are building moats — and which formula wins.
Beyond the Hype: What AI Slop Reveals About the Next Wave of B2B AI
AI slop isn't just a content problem — it's a workflow design problem. We break down the jagged frontier of AI capability and what it means for founders building the next generation of B2B AI tools.
MCED FDA Approval Challenges: Why Multi-Cancer Blood Tests Remain Out-of-Pocket
Why MCED tests haven't achieved FDA approval: Analysis of positive predictive value issues, clinical evidence barriers, and diagnostic costs. Plus market potential insights.
HeartFlow IPO Analysis: Medical AI Company IPO Success Story
HeartFlow's IPO marks the first pure-play medical AI company to reach public markets with 99% AI revenue. Analysis of business model, financials, and roadmap for medical AI startups.
